Conatus Pharmaceuticals Trading Down 10.9% on Analyst Downgrade (CNAT)
Conatus Pharmaceuticals (NASDAQ:CNAT)’s share price traded down 10.9% on Thursday after Stifel Nicolaus lowered their price target on the stock from $14.00 to $13.00, Stock Ratings News reports. Stifel Nicolaus currently has a buy rating on the stock. Conatus Pharmaceuticals traded as low as $6.56 and last traded at $6.93, with a volume of 757,736 shares trading hands. The stock had previously closed at $7.78.
Separately, analysts at Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Friday, June 13th. They set a “buy” rating and a $19.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $16.00.
The stock has a 50-day moving average of $7.89 and a 200-day moving average of $8.22. The company’s market cap is $107.7 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.34) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.06. Analysts expect that Conatus Pharmaceuticals will post $-1.66 earnings per share for the current fiscal year.
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of medicines to treat liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.